CDNA shares climb after AlloHeme data show early AML/MDS relapse detection, backing its Transplant+ expansion into cell ...
A novel blood based surveillance test using artificial intelligence and next-generation sequencing identified relapse a median of 41 days before clinical detection in patients with AML or MDS ...
CareDx (NASDAQ:CDNA) used an investor webcast to outline its “Transplant Plus” expansion into cell therapy and to highlight ...
The AML Compliance Officer and accounting leadership should co-own key control interfaces. This includes data standards, reconciliation rules, escalation thresholds, and periodic control assurance ...
The successful clinical validation of AlloHeme represents a key milestone in CareDx's Transplant+ strategy, expanding the Company's precision medicine capabilities into cell therapy, hematology, and ...
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat ® KMT2A + MRD Assay and Software to its industry-leading ...
An observational study recently published in Cancer highlights a notable correlation between glucose-6-phosphate dehydrogenase (G6PD) deficiency and improved clinical outcomes among patients with ...
Cryptopolitan on MSN
Crypto.com becomes first exchange to receive AI management certification
Crypto.com has become the first digital asset platform to secure ISO/IEC 42001:2023 certification. This is the international standard for an Artificial Intelligence Management System (AIMS). The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results